New target for treating diabetic kidney disease, the leading cause of kidney failure

Researchers have discovered a new therapeutic target for diabetic nephropathy, the leading cause of kidney failure. The findings, appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN), could help protect the kidney health of individuals with diabetes.

While it's unclear precisely how diabetic nephropathy—kidney disease or damage that occurs in people with diabetes—develops, inflammation is likely involved. One particular inflammatory molecule, osteopontin, seems to play a prominent role, making it a potential target for future therapies.

In an attempt to inhibit osteopontin expression, Daisuke Ogawa, MD, PhD (Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, in Japan) and his colleagues tried activating a receptor that blocks the expression of genes involved in inflammation. This receptor, liver x receptor (LXR), can be activated with a drug named T0901317.

When with were given T0901317, the animals' kidneys became healthier and functioned better. Also, the T0901317 treatment markedly decreased the expression of osteoponin and other inflammatory molecules in the kidneys. Laboratory experiments with revealed that high sugar concentrations—like those seen in the blood of diabetics—increased osteopontin expression, which could be inhibited with T0901317.

"These observations support an important role for LXR agonists in suppressing the inflammatory responses in diabetic kidneys and preventing the development of nephropathy," said Dr. Ogawa.

More information: The article, entitled "Activation of Liver X Receptor Inhibits Osteopontin and Ameliorates Diabetic Nephropathy," will appear online on October 18, 2012, doi: 10.1681/ASN.2012010022

add to favorites email to friend print save as pdf

Related Stories

Research aims to prevent diabetic kidney failure

Nov 05, 2011

The enzyme arginase-2 plays a major role in kidney failure, and blocking the action of this enzyme might lead to protection against renal disease in diabetes, according to researchers.

New treatment target for diabetic kidney disease

May 27, 2011

(Medical Xpress) -- UC Davis investigators have shown that blocking a specific receptor pathway could slow or even prevent diabetic nephropathy — an often fatal complication of diabetes for which there are few good treatment ...

Recommended for you

Restrictions lifted at British bird flu farm

18 minutes ago

Britain on Sunday lifted all restrictions at a duck farm in northern England after last month's outbreak of H5N8 bird flu, the same strain seen in recent cases across Europe.

Recorded Ebola deaths top 7,000

23 hours ago

The worst Ebola outbreak on record has now killed more than 7,000 people, with many of the latest deaths reported in Sierra Leone, the World Health Organization said as United Nations Secretary-General Ban ...

Liberia holds Senate vote amid Ebola fears (Update)

Dec 20, 2014

Health workers manned polling stations across Liberia on Saturday as voters cast their ballots in a twice-delayed Senate election that has been criticized for its potential to spread the deadly Ebola disease.

Evidence-based recs issued for systemic care in psoriasis

Dec 19, 2014

(HealthDay)—For appropriately selected patients with psoriasis, combining biologics with other systemic treatments, including phototherapy, oral medications, or other biologic, may result in greater efficacy ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.